Prolonged effects of poly(lactic-co-glycolic acid) microsphere-containing huperzine A on mouse memory dysfunction induced by scopolamine

Basic and Clinical Pharmacology and Toxicology

Volumn 100, Issue 3, 2007, Pages 190-195

  Wang, Chaoyun ^a,b,c   Zhang, Taiping ^c   Ma, Hongmei ^d   Liu, Juntian ^a,b   Fu, Fenghua ^c   Liu, Ke ^c  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c Shandong Engineering Research Center for Nature Drug   (China)

^d CHINA AGRICULTURAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; HUPERZINE A; MICROSPHERE; POLYGLACTIN; SCOPOLAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFECT; ENZYME ACTIVITY; EXPERIMENTAL MODEL; LATENT PERIOD; LOW DRUG DOSE; MALE; MEMORY DISORDER; MOUSE; NEUROPROTECTION; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; SPECTROPHOTOMETRY; TASK PERFORMANCE; TIME; TREATMENT OUTCOME;

ACETYLCHOLINESTERASE; ANIMALS; AVOIDANCE LEARNING; CEREBRAL CORTEX; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; LACTIC ACID; MALE; MEMORY DISORDERS; MICE; MICROSPHERES; MUSCARINIC ANTAGONISTS; NEUROPROTECTIVE AGENTS; POLYGLYCOLIC ACID; POLYMERS; REACTION TIME; SCOPOLAMINE; SESQUITERPENES; SPECTROPHOTOMETRY;

EID: 33847045172     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2007.00041.x     Document Type: Article

References (23)

1. Blockland A. Acetylcholine: a neurotransmitter for learning and memory? Brain Res 1996;21:285-300.
2. Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2:1403.
3. Davis KL, Yamamura HI. Cholinergic underactivity in human memory disorders. Life Sci 1978;23:1729-34.
4. Hagan JJ, Jansen JHM, Broekkamp CLE. Blockade of spatial learning by the M1 muscarinic antagonist pirenzepine. Psychopharmacology 1987;93:470-6.
5. Giacobini E. New trends in cholinergic therapy for Alzheimer disease: nicotinic agonists or cholinesterase inhibitors? Prog Brain Res 1996;109:311-23.
6. Shafferman A, Kronman C, Flashner Y et al. Mutagenesis of human acetylcholinesterase Identification of residues involved in catalytic activity and in polypeptide folding. J Biol Chem 1992;267:640-8.
7. Tang XC, HanYF. Pharmacological profile of huperzine A, a novel acetylcholinesterase inhibitor from Chinese herb. CNS Drugs Review 1999;5:281-300.
8. Baker RW. Controlled Release of Biologically Active Agents. Wiley, New York, 1987.
9. Chasin M, Langer R. Biodegradable Polymers as Drug Delivery Systems. Drugs and the Pharmaceutical Sciences. Marcel Dekker, New York, 1990;45.
10. Benita S. Microencapsulation: Methods and Industrial Applications. Drugs and the Pharmaceutical Sciences. Marcel Dekker, New York, 1996;73.
11. Washington C. Drug release from microparticulate systems. In: Benita S (eds). Microencapsulation: Methods and Industrial Applications. Drugs and the Pharmaceutical Sciences. Marcel Dekker, New York, 1996;155-81.
12. Brioni JD, Hock FJ, McGaugh JJ. Drug effects on learning and memory. In: Vogel GH, Vogel WH (eds). Drug Discovery and Evaluation: Pharmacological Assays. Springer, New York, 1997;335-6.
13. Moral-naranjo MT, Cabezas-herrera J, Vidal CJ. Molecular forms of acetyl- and butyrylcholinesterases in normal and dystrophic mouse brain. J Neurosci Res 1996;43:224-34.
14. Lowry OH, Rosebrough NJ, Farr AI, Randall RJ. Protein measurement with folin phenol reagent. J Biol Chem 1951;193:265-75.
15. Fibiger HC. Central cholinergic systems and memory. In: Squire LR, Lindenlaub E (eds). The Biology of Memory. Symposia Medica Hoechst. Springer-Verlag, New York, 1990;23.
16. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction: a critical review. Science 1982;217:408-17.
17. Enz A, Amstutz R, Boddeke H, Gmelin G, Malanowski J. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy of Alzheimer's disease. Prog Brain Res 1993;98:431-8.
18. Siddiqui MF, Levey AI. Cholinergic therapies in Alzheimer's disease. Drugs Future 1999;24:417-44.
19. Bartus JD, Johnson HR. Short-term memory in the rhesus monkey: disruption from the anti-cholinergic scopolamine. Pharmacol Biochem Behav 1976;5:39-46.
20. Sitaram N, Weingartner H, Gillin JC. Human serial learning: enhancement with arecholine and choline impairment with scopolamine. Science 1978;211:274-6.
21. Amitava D, Girja S, Chandishwar N, Raghwendra P, Satyawan S, Hemant KS. A comparative study in rodents of standardized extracts of Bacopa monniera and Ginkgo biloba anticholinesterase and cognitive enhancing activities. Pharmacol Biochem Behav 2002;73:893-900.
22. Cory B, Martin K, Amanda C, Kyekyoon K, Daniel WP. Precise control of PLG microsphere size provides enhanced control of drug release rate. J Control Release 2002; 82:137-47.
23. Chu DF, Fu XQ, Liu WH, Liu K, Li YX. Pharmacokinetics and in vitro and in vivo correlation of huperzine A loaded poly(lactic-co-glycolic acid) microspheres in dogs. Int J Pharm 2006;325:116-23.